Helicobacter pylori infection historical perspective: Difference between revisions
| Line 11: | Line 11: | ||
*In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.<ref name="pmid8007082">{{cite journal |vauthors= |title=NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease |journal=JAMA |volume=272 |issue=1 |pages=65–9 |year=1994 |pmid=8007082 |doi= |url=}}</ref> | *In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.<ref name="pmid8007082">{{cite journal |vauthors= |title=NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease |journal=JAMA |volume=272 |issue=1 |pages=65–9 |year=1994 |pmid=8007082 |doi= |url=}}</ref> | ||
*In 1994, the International Agency for Research on Cancer (IARC) concluded that ''[[H.pylori]]'' is a group I human carcinogen for gastric adenocarcinoma.<ref name="pmid9103907">{{cite journal |vauthors=Tanida N, Sakagami T, Sawada Y, Shimoyama T |title=[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori] |language=Japanese |journal=Nippon Rinsho |volume=55 |issue=4 |pages=995–1002 |year=1997 |pmid=9103907 |doi= |url=}}</ref> | *In 1994, the International Agency for Research on Cancer (IARC) concluded that ''[[H.pylori]]'' is a group I human carcinogen for gastric adenocarcinoma.<ref name="pmid9103907">{{cite journal |vauthors=Tanida N, Sakagami T, Sawada Y, Shimoyama T |title=[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori] |language=Japanese |journal=Nippon Rinsho |volume=55 |issue=4 |pages=995–1002 |year=1997 |pmid=9103907 |doi= |url=}}</ref> | ||
*In 1997, FDA approved three H.pylori regimens for the eradication of H. pylori infection. They are<ref name="pmid9394774">{{cite journal |vauthors=Hopkins RJ |title=Current FDA-approved treatments for Helicobacter pylori and the FDA approval process |journal=Gastroenterology |volume=113 |issue=6 Suppl |pages=S126–30 |year=1997 |pmid=9394774 |doi= |url=}}</ref> | |||
:*Regimen 1: Omeprazole+ clarithromycin | |||
:*Regimen 2: Ranitinine-Bismuth-Citrate + Clarithromycin | |||
:*Regimen 3: Bismuth subsalicylate + metronidazole + Tetracycline + an H2 receptor antagonist | |||
Revision as of 15:40, 15 December 2016
|
Helicobacter pylori infection Microchapters |
|
Differentiating Helicobacter pylori infection from other Diseases |
|---|
|
Diagnosis |
|
Guideline Recommendation |
|
Treatment |
|
Case Studies |
|
Helicobacter pylori infection historical perspective On the Web |
|
American Roentgen Ray Society Images of Helicobacter pylori infection historical perspective |
|
Helicobacter pylori infection historical perspective in the news |
|
Blogs on Helicobacter pylori infection historical perspective |
|
Directions to Hospitals Treating Helicobacter pylori infection |
|
Risk calculators and risk factors for Helicobacter pylori infection historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]
Overview
It was identified in 1982 by Barry Marshall and Robin Warren, who found that it was present in patients with chronic gastritis and gastric ulcers, conditions that were not previously believed to have a microbial cause.
Historical Perspective
- The association between Helicobacter pylori and peptic ulcers was made by Barry Marshall and Robin Warren in the year 1984.[1][2][3][4]
- In 2005, Barry Marshall and Robin Warren won Nobel prize in physiology or medicine for their "discovery of bacterium Helicobacter pylori and and its role in gastritis and peptic ulcer disease".
- In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.[5]
- In 1994, the International Agency for Research on Cancer (IARC) concluded that H.pylori is a group I human carcinogen for gastric adenocarcinoma.[6]
- In 1997, FDA approved three H.pylori regimens for the eradication of H. pylori infection. They are[7]
- Regimen 1: Omeprazole+ clarithromycin
- Regimen 2: Ranitinine-Bismuth-Citrate + Clarithromycin
- Regimen 3: Bismuth subsalicylate + metronidazole + Tetracycline + an H2 receptor antagonist
1995
Data show that about 75 percent of ulcer patients are still treated primarily with antisecretory medications, and only 5 percent receive antibiotic therapy. Consumer research by the American Digestive Health Foundation finds that nearly 90 percent of ulcer sufferers are unaware that H. pylori causes ulcers. In fact, nearly 90 percent of those with ulcers blame their ulcers on stress or worry, and 60 percent point to diet.
1996
The Food and Drug Administration approves the first antibiotic for treatment of ulcer disease.
1997
The Centers for Disease Control and Prevention (CDC), with other government agencies, academic institutions, and industry, launches a national education campaign to inform health care providers and consumers about the link between H. pylori and ulcers. This campaign reinforces the news that ulcers are a curable infection, and the fact that health can be greatly improved and money saved by disseminating information about H. pylori. Medical researchers sequence the H. pylori genome. This discovery can help scientists better understand the bacterium and design more effective drugs to fight it.
References
- ↑ Fock KM, Graham DY, Malfertheiner P (2013). "Helicobacter pylori research: historical insights and future directions". Nat Rev Gastroenterol Hepatol. 10 (8): 495–500. doi:10.1038/nrgastro.2013.96. PMC 3973742. PMID 23752823.
- ↑ Kusters JG, van Vliet AH, Kuipers EJ (2006). "Pathogenesis of Helicobacter pylori infection". Clin Microbiol Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
- ↑ "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". Lancet. 1 (8336): 1273–5. 1983. PMID 6134060.
- ↑ Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985). "Attempt to fulfil Koch's postulates for pyloric Campylobacter". Med J Aust. 142 (8): 436–9. PMID 3982345.
- ↑ "NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease". JAMA. 272 (1): 65–9. 1994. PMID 8007082.
- ↑ Tanida N, Sakagami T, Sawada Y, Shimoyama T (1997). "[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori]". Nippon Rinsho (in Japanese). 55 (4): 995–1002. PMID 9103907.
- ↑ Hopkins RJ (1997). "Current FDA-approved treatments for Helicobacter pylori and the FDA approval process". Gastroenterology. 113 (6 Suppl): S126–30. PMID 9394774.